NovoCure (NASDAQ:NVCR) will issue its quarterly earnings data before the market opens on Thursday, July 29th. Analysts expect the company to announce earnings of $0.02 per share for the quarter. Parties that are interested in participating in the company's conference call can do so using this link.
NovoCure (NASDAQ:NVCR) last issued its earnings results on Thursday, April 29th. The medical equipment provider reported ($0.04) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.02 by ($0.06). NovoCure had a net margin of 2.22% and a return on equity of 3.30%. The firm had revenue of $134.70 million during the quarter, compared to analyst estimates of $136.54 million. On average, analysts expect NovoCure to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of NASDAQ:NVCR opened at $190.00 on Thursday. NovoCure has a 52 week low of $64.00 and a 52 week high of $232.76. The company has a debt-to-equity ratio of 1.50, a current ratio of 9.19 and a quick ratio of 8.94. The firm has a fifty day moving average price of $199.88. The firm has a market cap of $19.65 billion, a P/E ratio of 1,727.43 and a beta of 1.08.
NVCR has been the topic of several recent analyst reports. Piper Sandler boosted their target price on shares of NovoCure from $235.00 to $240.00 and gave the company an "overweight" rating in a research note on Friday, July 9th. Wells Fargo & Company lifted their price target on NovoCure from $135.00 to $215.00 and gave the company an "equal weight" rating in a report on Tuesday, April 13th. Truist lifted their price target on NovoCure from $132.00 to $142.00 in a report on Monday, April 19th. Truist Securities lifted their price target on NovoCure from $132.00 to $142.00 and gave the company a "hold" rating in a report on Monday, April 19th. Finally, Zacks Investment Research cut NovoCure from a "hold" rating to a "sell" rating in a report on Thursday, July 8th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the stock. NovoCure currently has a consensus rating of "Hold" and a consensus target price of $196.00.
In other NovoCure news, Director Gabriel Leung sold 1,000 shares of the business's stock in a transaction dated Wednesday, May 5th. The stock was sold at an average price of $199.67, for a total transaction of $199,670.00. Following the completion of the sale, the director now directly owns 73,045 shares of the company's stock, valued at approximately $14,584,895.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ely Benaim sold 1,833 shares of the business's stock in a transaction dated Monday, May 10th. The stock was sold at an average price of $189.65, for a total value of $347,628.45. Following the sale, the insider now directly owns 35,092 shares of the company's stock, valued at $6,655,197.80. The disclosure for this sale can be found here. Insiders have sold a total of 31,496 shares of company stock valued at $6,620,663 over the last three months. Company insiders own 4.57% of the company's stock.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma.
Further Reading: Analyst Ratings
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider NovoCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NovoCure wasn't on the list.
While NovoCure currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here